HealthQuill National Kidney Foundation
The USFDA has approved Calliditas Therapeutics’ oral drug to treat loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) and at risk of disease progression.
Drugs Health Pharma

Sweden’s Calliditas gets FDA nod for oral drug to treat kidney loss function

HQ Team December 21, 2023: Sweden’s Calliditas Therapeutics has got the USFDA green light for its oral drug to treat loss of kidney.

Read More
X